Taken together, our data encourage further investigation by clinical trial to explore whether downregulating pathological angiogenesis has clinical utility, especially in patients with severe psoriasis or those with elevated levels of VEGF‐A in plasma and/or skin. Here, VEGFA is linked to psoriasis.